These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2908814)
1. Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam. Cregeen RJ; Rudge PJ; Mills JG; Vincent SH; Burland WL J Hypertens Suppl; 1985 Dec; 3(3):S173-5. PubMed ID: 2908814 [TBL] [Abstract][Full Text] [Related]
2. Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses. Eades SC; Moore JN Am J Vet Res; 1993 Jan; 54(1):122-5. PubMed ID: 8093992 [TBL] [Abstract][Full Text] [Related]
3. Human vasodilator responses to a dopamine agonist: possible mechanisms. Redman D; Thom SA; Hughes AD; Hasan S; Sever PS J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam. Christie MI; Smith GW J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731 [TBL] [Abstract][Full Text] [Related]
5. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat. Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375 [TBL] [Abstract][Full Text] [Related]
6. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029 [TBL] [Abstract][Full Text] [Related]
7. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam. Hedge SS; Ricci A; Amenta F; Lokhandwala MF J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow. Zhao RR; Wang PH; Zhang WF; Fennell WH Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog. Kinter LB; Horner E; Mann WA; Weinstock J; Ruffolo RR Chirality; 1990; 2(4):219-25. PubMed ID: 1982058 [TBL] [Abstract][Full Text] [Related]
10. Effects of fenoldopam on cecal blood flow and mechanical activity in horses. Clark ES; Moore JN Am J Vet Res; 1989 Nov; 50(11):1926-30. PubMed ID: 2575878 [TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study. Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231 [TBL] [Abstract][Full Text] [Related]
12. Evidence against a role for dopamine D1 receptors in the myocardium of the pig. Van Woerkens LJ; Duncker DJ; Den Boer MO; McFalls EO; Sassen LM; Saxena PR; Verdouw PD Br J Pharmacol; 1991 Sep; 104(1):246-50. PubMed ID: 1686206 [TBL] [Abstract][Full Text] [Related]
13. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613 [TBL] [Abstract][Full Text] [Related]
14. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Girbes AR; Smit AJ; Meijer S; Reitsma WD Nephron; 1990; 56(2):179-85. PubMed ID: 1978736 [TBL] [Abstract][Full Text] [Related]